Clinical trials: Diffuse Large B-Cell Leukemia
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases
RATIONALE: Giving chemotherapy before a donor peripheral stem cell transplant or bone marrow transplant using stem cells from a brother or sister that closely match the patient's stem cells, helps stop the growth of cancer or…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00438958
- Testing
- filgrastim, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 230 people
- Sponsor
- The Canadian Blood and Marrow Transplant Group
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor stem cell helps stop the growth of cancer or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00003816
- Testing
- anti-thymocyte globulin, busulfan, carboplatin
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Roswell Park Cancer Institute
Lymphoma
Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00004908
- Testing
- cyclophosphamide, peripheral blood stem cell transplantation, radiation therapy
- Where
- United States
- Sponsor
- Northwestern University
Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia (ALL)
Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data
This retrospective cohort study, based on the French medico-administrative database (SNDS), evaluated the care pathway, the effectiveness of management and the costs associated with patients treated with chimeric antigen receptor…
- Trial name
- NCT06392763
- Where
- France
- Volunteers
- 602 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant (UCBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT01093586
- Testing
- double-unit umbilical cord blood transplantation, cytogenetic analysis, bone marrow aspiration
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center
B Cell Malignancies, Acute Lymphobkastic Leukemia
A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies
This is a phase I/II trial of SHB-02-CD19, T-cell expressing an anti-CD19 Chimeric-Antigen-Receptor (CAR) in patients with CD19 expressing B-cell malignancies.
- Conditions
- B Cell Malignancies, Acute Lymphobkastic Leukemia, Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)
- Trial name
- NCT07503353
- Testing
- SHB-02-CD19 (anti CD19 CAR-T cells)
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Sheba Medical Center
Leukemia, Lymphoma
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00891137
- Testing
- human myeloid progenitor cells
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cellerant Therapeutics
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and melphalan, before a donor peripheral stem cell transplant or bone marrow transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00453206
- Testing
- allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Wake Forest University Health Sciences
Cancer
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing cytomegalovirus in patients undergoing stem cell…
- Trial name
- NCT00045292
- Testing
- acyclovir, acyclovir sodium, valacyclovir
- Where
- 6 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, in Relapse
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
This is an open-label, single-arm, phase I clinical trial with dose escalation designed to investigate the safety, tolerability, and pharmacokinetic properties of Human CD19-CD22 Targeted T Cells Infusion.
- Conditions
- Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin Lymphoma, B-cell, Diffuse Large B Cell Lymphoma
- Trial name
- BAH241 (NCT06213636)
- Testing
- CD19/CD22-CAR T cells
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Essen Biotech
Non-Hodgkin Lymphoma
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
The purpose of the study was to assess the efficacy and safety of tisagenlecleucel in pediatric, adolescent and young adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) including Burkitt Lymphoma and…
- Trial name
- BIANCA (NCT03610724)
- Testing
- Tisagenlecleucel, lymphodepleting chemotherapy, Bridging Therapy
- Where
- 26 sites in United States, Australia and 12 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Myeloproliferative Disorders, Kidney Cancer
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00787761
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northside Hospital, Inc.
Leukemia, Lymphoma
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00005854
- Testing
- cyclophosphamide, cyclosporine, methotrexate
- Where
- 4 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Treatment for Chronic Pain in Patients With Advanced Cancer
RATIONALE: Different drug formulations and combinations of drugs may help patients with chronic pain live more comfortably. It is not yet known which regimen is most effective for chronic pain.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003687
- Testing
- dextromethorphan hydrobromide, morphine sulfate
- Where
- 4 sites in Canada
- Volunteers
- 87 people
- Sponsor
- NCIC Clinical Trials Group
AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma
Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. This phase II trial is studying how well topotecan hydrochloride works in treating children with meningeal cancer that…
- Conditions
- AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma
- Trial name
- NCT00005811
- Testing
- topotecan hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
RATIONALE: Giving chemotherapy, such as cyclophosphamide and busulfan, and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00612716
- Testing
- busulfan, cyclophosphamide, Stem cell infusion
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lymphoma
Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00028665
- Testing
- filgrastim, rituximab, carmustine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Case Comprehensive Cancer Center
Cancer
Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to chronic graft-versus-host disease in patients who…
- Trial name
- NCT00957736
- Testing
- polymorphism analysis, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 252 people
- Sponsor
- Vanderbilt-Ingram Cancer Center